Stocks to Sell

Stocks can plunge for any number of reasons — investors may need to raise cash for large milestone purchases, or algorithms could be triggered by stop losses which create massive selloffs. Whatever the case, InvestorPlace’s journalists weed out the markets’ losers, keeping you informed of which stocks to cash out of before they come crashing down.

10 Worst “Strong Sell” Stocks This Week — EXK ABX MCP and more

By Portfolio Grader
This week, these ten stocks have the worst year-to-date performance. Each of these also rates an "F" ("strong sell") on Portfolio Grader. Since the beginning of the year, the Nasdaq rose 10.9%, the Dow is up 13.2% and the S&P has increased 12.1%.

7 Energy Services Stocks to Sell Now

By Portfolio Grader
The ratings of seven energy services stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

3 Construction and Engineering Stocks to Sell Now

By Portfolio Grader
This week, the overall grades of three construction and engineering stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

4 Software Stocks to Sell Now

By Portfolio Grader
For the current week, the overall ratings of four software stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

4 “Defensive” Stocks to Sell Now

By Lawrence Meyers, InvestorPlace Contributor
At a certain point, even defensive stocks can become vulnerable. You're better off selling these four "defensive" stocks.

5 Stocks With Ugly Earnings Momentum — FNBN NAV SGK LGCY VNR

By Portfolio Grader
This week, these five stocks have the worst ratings in Earnings Momentum, one of the eight Fundamental Categories on Portfolio Grader.

WTW – Time to Trim Weight Watchers Holdings

By Louis Navellier, Editor, Growth Investor
Weight Watchers is expected to show both top and bottom line decreases, and investors may want to pare back on holdings.

7 Semiconductor Stocks to Sell Now

By Portfolio Grader
This week, the ratings of seven semiconductor stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

7 Biotechnology Stocks to Sell Now

By Portfolio Grader
This week, the ratings of seven biotechnology stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

5 Stocks With Crummy Earnings Growth — KWK GNK SOL CRK LM

By Portfolio Grader
This week, these five stocks have the worst ratings in Earnings Growth, one of the eight Fundamental Categories on Portfolio Grader.

5 Stocks With Bad Cash Flow — KWK STP ATPG EDN AONE

By Portfolio Grader
This week, these five stocks have the worst ratings in Cash Flow, one of the eight Fundamental Categories on Portfolio Grader.

Gold, Gold Stocks Are Tarnished – Sell NOW!

By Lawrence Meyers, InvestorPlace Contributor
The perfect storm that buoyed gold to near $2,000 has dissipated, and the current situation is weak. Here's why you should bail out of gold and gold stocks now.

5 Stocks to Sell in December

By Sam Collins, InvestorPlace Chief Technical Analyst
Unlike most large-cap stocks, EBAY, IBM, NTGR, TGT and UTEK are not likely to rally into year-end, making them stocks to sell.

PBR Stock Update – Why Petrobras Is Plummeting

By Aaron Levitt, InvestorPlace Contributor
Petrobras unveiled a new pricing formula for its refined products. Unfortunately for PBR stock investors, it lacks transparency and shares have plunged.

5 Stocks With Crummy Sales Growth — NAVB CTEL HKTV CUR IMMU

By Portfolio Grader
This week, these five stocks have the worst ratings in Sales Growth, one of the eight Fundamental Categories on Portfolio Grader.

5 Stocks With Awful Operating Margin Growth — SYUT CTEL HKTV NYNY IMMU

By Portfolio Grader
This week, these five stocks have the worst ratings in Operating Margin Growth, one of the eight Fundamental Categories on Portfolio Grader.

Don’t Buy Orexigen on Diet Pill Hopes

By James Brumley, InvestorPlace Feature Writer
Orexigen Therapeutics joins VIVUS and Arena Pharmaceuticals in an industry that's brought nothing but disappointment to investors: weight-loss drugs.

4 Capital Markets Stocks to Sell Now

By Portfolio Grader
The overall ratings of four capital markets stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

3 Medical Devices Stocks to Sell Now

By Portfolio Grader
This week, the ratings of three medical devices stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Load More Articles